Handelsbanken Fonder AB Has $872,000 Stock Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Handelsbanken Fonder AB raised its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 54.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 14,100 shares of the company’s stock after purchasing an additional 5,000 shares during the period. Handelsbanken Fonder AB’s holdings in Amphastar Pharmaceuticals were worth $872,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. McGlone Suttner Wealth Management Inc. acquired a new position in Amphastar Pharmaceuticals in the fourth quarter valued at approximately $28,000. China Universal Asset Management Co. Ltd. lifted its stake in shares of Amphastar Pharmaceuticals by 99.2% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,261 shares of the company’s stock valued at $58,000 after purchasing an additional 628 shares during the period. Covestor Ltd boosted its position in shares of Amphastar Pharmaceuticals by 859.0% in the 3rd quarter. Covestor Ltd now owns 1,966 shares of the company’s stock worth $90,000 after purchasing an additional 1,761 shares during the last quarter. Nisa Investment Advisors LLC grew its stake in shares of Amphastar Pharmaceuticals by 115.0% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,430 shares of the company’s stock worth $150,000 after purchasing an additional 1,300 shares during the period. Finally, Annex Advisory Services LLC bought a new stake in Amphastar Pharmaceuticals in the third quarter valued at about $204,000. Institutional investors own 65.09% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Needham & Company LLC restated a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Wednesday, April 10th. JPMorgan Chase & Co. assumed coverage on shares of Amphastar Pharmaceuticals in a research note on Tuesday, March 5th. They set an “overweight” rating and a $60.00 price objective on the stock. Finally, StockNews.com lowered shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, February 29th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $66.00.

Amphastar Pharmaceuticals Trading Up 2.2 %

NASDAQ:AMPH opened at $42.02 on Tuesday. The business’s 50-day simple moving average is $44.29 and its 200-day simple moving average is $50.91. Amphastar Pharmaceuticals, Inc. has a fifty-two week low of $35.69 and a fifty-two week high of $67.66. The company has a debt-to-equity ratio of 0.92, a current ratio of 2.17 and a quick ratio of 1.70. The stock has a market capitalization of $2.05 billion, a PE ratio of 16.29, a price-to-earnings-growth ratio of 0.98 and a beta of 0.85.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings results on Wednesday, February 28th. The company reported $0.81 earnings per share for the quarter, missing analysts’ consensus estimates of $0.84 by ($0.03). Amphastar Pharmaceuticals had a net margin of 21.34% and a return on equity of 26.95%. The company had revenue of $178.11 million during the quarter, compared to the consensus estimate of $174.90 million. Sell-side analysts expect that Amphastar Pharmaceuticals, Inc. will post 3.43 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Michael A. Zasloff sold 12,500 shares of the company’s stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $47.18, for a total transaction of $589,750.00. Following the completion of the transaction, the director now directly owns 21,326 shares of the company’s stock, valued at $1,006,160.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, Director Floyd F. Petersen sold 500 shares of the stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $53.10, for a total transaction of $26,550.00. Following the completion of the transaction, the director now owns 80,333 shares in the company, valued at $4,265,682.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Michael A. Zasloff sold 12,500 shares of Amphastar Pharmaceuticals stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $47.18, for a total transaction of $589,750.00. Following the completion of the sale, the director now owns 21,326 shares in the company, valued at $1,006,160.68. The disclosure for this sale can be found here. In the last ninety days, insiders sold 14,000 shares of company stock valued at $660,860. Company insiders own 27.10% of the company’s stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.